BCL2L11 and acute lymphoblastic leukemia: Targeting this pathway with γ-secretase inhibitor (NOTCH1 pathway inhibitor) releases the repression of BCL2L11 expression and consequently reverses the resistance of mature T-ALL to chemotherapy with Dexamethasone [46].